MDV3100

We have completed a Phase 3 clinical trial of MDV3100, our novel, oral ARSI in patients with advanced prostate cancer.

Medivation, in collaboration with Astellas, is currently evaluating MDV3100 in a comprehensive development program. The Phase 3 AFFIRM trial in men with advanced prostate cancer who were previously treated with docetaxel-based chemotherapy has shown significantly (P<0.0001) increase survival compared to placebo Click here for press release. The Phase 3 PREVAIL trial is currently enrolling men with advanced prostate cancer who have not yet received chemotherapy. The Phase 2 TERRAIN trial, comparing MDV3100 with bicalutamide, is currently enrolling men who have progressed while on LHRH analogue therapy or following surgical castration. A Phase 2 trial evaluating MDV3100 monotherapy is currently enrolling hormone-naïve patients.

For more information about our clinical studies, please contact Medivation at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.

For more information on the PREVAIL study, please visit www.prevailtrial.com or call the toll-free hotline in the U.S. and Canada at 1-888-243-4363.

For more information on the TERRAIN or hormone-naïve studies, please call the toll-free hotline in the U.S. and Canada at 1-800-888-7704 ext. 5473 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it